By analyzing the relationship between SII and ACM in patients with stages IIIB–IV EGFR-mutated lung adenocarcinoma, this study aims to provide a foundation for developing a prognostic tool to guide individualized treatment. This evidence concerns the gene EGFR and lung adenocarcinoma.